Next Article in Journal
The Immunomodulary Effects of Systematic Exercise in Older Adults and People with Parkinson’s Disease
Previous Article in Journal
Continuous Positive Airway Pressure Treatment in Patients with Alzheimer’s Disease: A Systematic Review
Previous Article in Special Issue
Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies
Open AccessReview

Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer

by Daniel Sur 1,2,†, Andrei Havasi 2,†, Calin Cainap 1,2,†, Gabriel Samasca 3,*,†, Claudia Burz 2,3,†, Ovidiu Balacescu 1,4,†, Iulia Lupan 5,†, Diana Deleanu 3,† and Alexandru Irimie 6,7,†
1
11th Department of Medical Oncology, University of Medicine and Pharmacy “Iuliu Hatieganu”, 400015 Cluj-Napoca, Romania
2
Department of Medical Oncology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 400015 Cluj-Napoca, Romania
3
Department of Immunology and Allergology, University of Medicine and Pharmacy “Iuliu Hatieganu”, 400162 Cluj-Napoca, Romania
4
Department of Functional Genomics, Proteomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 400015 Cluj-Napoca, Romania
5
Department of Molecular Biology and Biotehnology, Babeș-Bolyai University, 400084 Cluj-Napoca, Romania
6
11th Department of Oncological Surgery and Gynecological Oncology, “IuliuHatieganu” University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania
7
Department of Surgery, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 400015 Cluj-Napoca, Romania
*
Author to whom correspondence should be addressed.
All authors contributed equally to this work.
J. Clin. Med. 2020, 9(1), 182; https://doi.org/10.3390/jcm9010182 (registering DOI)
Received: 24 December 2019 / Revised: 3 January 2020 / Accepted: 7 January 2020 / Published: 9 January 2020
Chimeric antigen receptor (CAR) T-cell therapy represents a new genetically engineered method of immunotherapy for cancer. The patient’s T-cells are modified to express a specific receptor that sticks to the tumor antigen. This modified cell is then reintroduced into the patient’s body to fight the resilient cancer cells. After exhibiting positive results in hematological malignancies, this therapy is being proposed for solid tumors like colorectal cancer. The clinical data of CAR T-cell therapy in colorectal cancer is rather scarce. In this review, we summarize the current state of knowledge, challenges, and future perspectives of CAR T-cell therapy in colorectal cancer. A total of 22 articles were included in this review. Eligible studies were selected and reviewed by two researchers from 49 articles found on Pubmed, Web of Science, and clinicaltrials.gov. This therapy, at the moment, provides modest benefits in solid tumors. Not taking into consideration the high manufacturing and retail prices, there are still limitations like increased toxicities, relapses, and unfavorable tumor microenvironment for CAR T-cell therapy in colorectal cancer. View Full-Text
Keywords: Chimeric antigen receptor (CAR)T-cell; colorectal cancer; immunotherapy; toxicity; trials Chimeric antigen receptor (CAR)T-cell; colorectal cancer; immunotherapy; toxicity; trials
Show Figures

Figure 1

MDPI and ACS Style

Sur, D.; Havasi, A.; Cainap, C.; Samasca, G.; Burz, C.; Balacescu, O.; Lupan, I.; Deleanu, D.; Irimie, A. Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. J. Clin. Med. 2020, 9, 182.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop